RecruitingPhase 3NCT06074588
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Sacituzumab tirumotecan(biological)
- Enrollment
- 556 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- UCLA Hematology/Oncology - Santa Monica ( Site 0023), Los Angeles, California, United States
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001), Jacksonville, Florida, United States
- Mid Florida Hematology and Oncology Center ( Site 0005), Orange City, Florida, United States
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003), Marietta, Georgia, United States
- Karmanos Cancer Institute ( Site 0018), Detroit, Michigan, United States
- Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0027), Rochester, Minnesota, United States
- Hattiesburg Clinic Hematology/Oncology ( Site 0010), Hattiesburg, Mississippi, United States
- University Of Nebraska Medical Center ( Site 0011), Omaha, Nebraska, United States
- Englewood Hospital and Medical Center ( Site 0033), Englewood, New Jersey, United States
- Atlantic Health System Morristown Medical Center ( Site 0031), Morristown, New Jersey, United States
- Capital Health Medical Center - Hopewell ( Site 0006), Pennington, New Jersey, United States
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0015), Cincinnati, Ohio, United States
- Tennessee Oncology (0036), Nashville, Tennessee, United States
- University of Texas MD Anderson (0037), Houston, Texas, United States
- VCU Health Adult Outpatient Pavillion ( Site 0026), Richmond, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06074588 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.